Endocrine Abstracts

Introduction: Immune checkpoint inhibitors (ICIs) have gained popularity as a standard cancer treatment in recent years. IrAEs, or immune-related adverse events, are specific immunological side effects that are linked to ICIs. Thyroid dysfunction is a prevalent irAE, but the cause, severity, and clinical appearance might vary. The most frequent thyroid irAEs brought on by ICIs are destructive thyroiditis and hypothyroidism, whereas immune-related adrenal insuf...

Background: Treatment with immune checkpoint inhibitors (ICIs) for advanced malignancies has been associated with developing immune-related adverse events (irAEs) severe enough to require the cessation of life-saving tumor immunotherapy.Objectives: The present study aimed to identify predictive inflammatory markers of the development of immune-related thyroid dysfunctions in patients with cervical cancer (CC) and non–small cell lung cancer (NSCLC) t...

Background and aims: Diffused endemic goiter (DEG) development is not always explained by increased TSH levels. Most DEG patients (pts) have normal TSH concentrations, with tendency to decreased T4 and normal or slightly elevated T3. In the present study levels of thyroid hormones (TH) in pts with various degrees of thyroid size (TS) and weak iodine deficiency (ID) were analyzed.Material and methods: In total DEG 137pts, aged 2–16 years were studied...

Introduction: Mono or combination therapy with immune checkpoint inhibitors for malignancies causes thyroid dysfunction in the form of overt or subclinical hypothyroidism, or thyrotoxicosis. Thyrotoxicosis phase is often transient and in some cases so short that it cannot be diagnosed in time and the patient is examined late when hypothyroidism is confirmed. We describe a case of Cervical Cancer woman who developed transient thyrotoxicosis and later hypothyroidism after combin...